This site is a comprehensive resource for biotech enthusiasts, including investors, researchers, media, etc. You'll find information about drug discovery and development, the FDA approval process, and loads of links and information about specific drugs and biotech companies.
BiotechDueDiligence's Latest Posts
Another huge week in biotech and pharma news, analysis and discussion on Twitter as 2014 draws to a close. Catch up or review the week with the Tweets of the Week, curated by @23aloha. Patrick Soon-Shiong makes a $20M investment in $SRNE at $5.8 - certainly a encouraging development for the potential Abraxane competitor...— Ian Estepan (@ianestepan) December 15, 2014 @VikramKhanna_ The goal, however, is to get quality in the bargain bin.— David Sobek (@dsobek) December […]
Maybe you were in search of some light reading for the holidays?Edits to ethics code rankle: Clinical-trial obligations introduced into the Helsinki declaration called too onerous by some.Heidi Ledford. Nature News.Web Collection: Clinical applications of next-generation sequencingNature Biotechnology. $FMINature Outlook: Hemophilia (collection of open-access articles)Data Sharing, Year 1 — Access to Data from Industry-Sponsored Clinical TrialsStrom et al. New England Journal of […]
Another bonanza few days last week for biotech's...here is the weekly round-up, a.k.a. the $BLUE show. Thanks to @23aloha for the heavy lifting this week.EDIT: sorry for the blog issues, find this week's tweets at this link. [...]
Sorry for the delay, but the Tweets of the Week feature returns this weekend (maybe a newborn baby and a sick big brother is an acceptable excuse?). Hopefully you enjoy reliving the past couple weeks in the world or biotech, pharmaceuticals and drug development. Thanks as always to @23aloha for assistance in curating these blog entries. Here's my first video blog, and the rationale for 'why video'. Hope you like it. http://t.co/Wg5JnEcxvv— Brad Loncar (@bradloncar) […]
The Search for Exceptional GenomesAntonio Regalado (Technology Review) $REGNYes, there are good secondary offerings in biotechBrad Loncar (Loncar Blog) $RCPT $LXRXA Drug Regrew A Little Girl's Missing Bones. How Much Should That Cost?Matthew Herper (Forbes) $ALXNNIH and FDA Toughen Rules for Reporting Clinical Trial ResultsEd Silverman (Pharmalot / WSJ)Company's Compassion Leads to Clinical Hold on Experimental DrugAlec Gaffney (Regulatory Focus / RAPS) $CYTRA Billion Here, A Billion […]
Log in to leave a comment